Sectoral Asset Management’s Theravance Biopharma TBPH Stock Holding History

Sectoral Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,945	Closed	-$260K	–	133
2018 Q3	$260K	Buy	+7,945	New	+$217K	0.03%	122
2014 Q3	–	Sell	-152,151	Closed	-$4.85M	–	71
2014 Q2	$4.85M	Buy	+152,151	New	+$4.58M	0.21%	56

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sectoral Asset Management's TBPH Position: Q4 2018 in Review

Sectoral Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2018, closing a stake of 7,945 shares — an estimated $260K sold.

Sectoral Asset Management first reported a position in TBPH in Q2 2014 and held it in 2 quarters. The position peaked at $4.85M in Q2 2014. 96 funds tracked by Wall St. Rank hold TBPH as of Q4 2018.

Sectoral Asset Management reported no remaining Theravance Biopharma position as of Q4 2018 after selling out during the quarter.
Sectoral Asset Management sold 7,945 Theravance Biopharma shares in Q4 2018, an estimated $260K.
Sectoral Asset Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 2 quarters.
Sectoral Asset Management's Theravance Biopharma position peaked at $4.85M in Q2 2014.
96 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2018.

Based on Sectoral Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.